Literature DB >> 26755861

Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.

Christoph G Dietrich1, Oliver Götze1, Andreas Geier1.   

Abstract

Liver cirrhosis is the common endpoint of many hepatic diseases and represents a relevant risk for liver failure and hepatocellular carcinoma. The progress of liver fibrosis and cirrhosis is accompanied by deteriorating liver function. This review summarizes the regulatory and functional changes in phase I and phase II metabolic enzymes as well as transport proteins and provides an overview regarding lipid and glucose metabolism in cirrhotic patients. Interestingly, phase I enzymes are generally downregulated transcriptionally, while phase II enzymes are mostly preserved transcriptionally but are reduced in their function. Transport proteins are regulated in a specific way that resembles the molecular changes observed in obstructive cholestasis. Lipid and glucose metabolism are characterized by insulin resistance and catabolism, leading to the disturbance of energy expenditure and wasting. Possible non-invasive tests, especially breath tests, for components of liver metabolism are discussed. The heterogeneity and complexity of changes in hepatic metabolism complicate the assessment of liver function in individual patients. Additionally, studies in humans are rare, and species differences preclude the transferability of data from rodents to humans. In clinical practice, some established global scores or criteria form the basis for the functional evaluation of patients with liver cirrhosis, but difficult treatment decisions such as selection for transplantation or resection require further research regarding the application of existing non-invasive tests and the development of more specific tests.

Entities:  

Keywords:  Breath tests; Drug metabolism; Glucose metabolism; Lipid metabolism; Liver cirrhosis; Transport

Mesh:

Substances:

Year:  2016        PMID: 26755861      PMCID: PMC4698509          DOI: 10.3748/wjg.v22.i1.72

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  163 in total

Review 1.  Pharmacogenetics of cytochromes P450.

Authors:  J A Hasler
Journal:  Mol Aspects Med       Date:  1999 Feb-Apr

2.  Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis.

Authors:  D J McConn; Y S Lin; T L Mathisen; D K Blough; Y Xu; T Hashizume; S L Taylor; K E Thummel; M C Shuhart
Journal:  Clin Pharmacol Ther       Date:  2009-02-11       Impact factor: 6.875

Review 3.  Characterization of animal models for primary sclerosing cholangitis (PSC).

Authors:  Peter Fickert; Marion J Pollheimer; Ulrich Beuers; Carolin Lackner; Gideon Hirschfield; Chantal Housset; Verena Keitel; Christoph Schramm; Hanns-Ulrich Marschall; Tom H Karlsen; Espen Melum; Arthur Kaser; Bertus Eksteen; Mario Strazzabosco; Michael Manns; Michael Trauner
Journal:  J Hepatol       Date:  2014-02-19       Impact factor: 25.083

4.  Synthesis and biological evaluation of technetium-99m labeled galactose derivatives as potential asialoglycoprotein receptor probes in a hepatic fibrosis mouse model.

Authors:  Wen-Yi Chang; Hao-Wen Kao; Hsin-Ell Wang; Jenn-Tzong Chen; Wuu-Jyh Lin; Shyh-Jen Wang; Chuan-Lin Chen
Journal:  Bioorg Med Chem Lett       Date:  2013-09-13       Impact factor: 2.823

5.  Plasma disappearance rate of indocyanine green in liver dysfunction.

Authors:  P Faybik; H Hetz
Journal:  Transplant Proc       Date:  2006-04       Impact factor: 1.066

Review 6.  Experimental models of hepatic fibrosis: a review.

Authors:  H Tsukamoto; M Matsuoka; S W French
Journal:  Semin Liver Dis       Date:  1990-02       Impact factor: 6.115

Review 7.  The model for end-stage liver disease (MELD).

Authors:  Patrick S Kamath; W Ray Kim
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

8.  Downregulation of breast cancer resistance protein in colon adenomas reduces cellular xenobiotic resistance and leads to accumulation of a food-derived carcinogen.

Authors:  Christoph G Dietrich; Ann-Kathrin Vehr; Ina V Martin; Nikolaus Gassler; Timo Rath; Elke Roeb; Johannes Schmitt; Christian Trautwein; Andreas Geier
Journal:  Int J Cancer       Date:  2011-05-05       Impact factor: 7.396

9.  Alterations in glucose metabolism associated with liver cirrhosis persist in the clinically stable long-term course after liver transplantation.

Authors:  Uwe J F Tietge; Oliver Selberg; Andreas Kreter; Matthias J Bahr; Matthias Pirlich; Wolfgang Burchert; Manfred J Müller; Michael P Manns; Klaus H W Böker
Journal:  Liver Transpl       Date:  2004-08       Impact factor: 5.799

10.  CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores.

Authors:  Albader Albarmawi; David Czock; Annika Gauss; Robert Ehehalt; Justo Lorenzo Bermejo; Jürgen Burhenne; Tom M Ganten; Peter Sauer; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

View more
  14 in total

1.  Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp.

Authors:  Fan Wang; Ming-Xing Miao; Bin-Bin Sun; Zhong-Jian Wang; Xian-Ge Tang; Yang Chen; Kai-Jing Zhao; Xiao-Dong Liu; Li Liu
Journal:  Acta Pharmacol Sin       Date:  2017-08-03       Impact factor: 6.150

2.  Phase 0 of the Xenobiotic Response: Nuclear Receptors and Other Transcription Factors as a First Step in Protection from Xenobiotics.

Authors:  William S Baldwin
Journal:  Nucl Receptor Res       Date:  2019-11-20

Review 3.  An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist.

Authors:  Pankaj Puri; Narendra Kotwal
Journal:  J Clin Exp Hepatol       Date:  2021-09-16

4.  GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition.

Authors:  Eloïne Bestion; Zuzana Macek Jilkova; Jean-Louis Mège; Marie Novello; Keerthi Kurma; Seyedeh Tayebeh Ahmad Pour; Gilles Lalmanach; Lise Vanderlynden; Lionel Fizanne; Firas Bassissi; Madani Rachid; Jennifer Tracz; Jérôme Boursier; Jérôme Courcambeck; Cindy Serdjebi; Christelle Ansaldi; Thomas Decaens; Philippe Halfon; Sonia Brun
Journal:  Ther Adv Chronic Dis       Date:  2020-07-16       Impact factor: 5.091

5.  Vitamin D Deficiency and Its Relationship with Child-Pugh Class in Patients with Chronic Liver Disease.

Authors:  Zubia Jamil; Sharmin Arif; Anum Khan; Asghar Aurangzeb Durrani; Nayyar Yaqoob
Journal:  J Clin Transl Hepatol       Date:  2018-02-01

6.  Physiologically-Based Pharmacokinetic Model of Morphine and Morphine-3-Glucuronide in Nonalcoholic Steatohepatitis.

Authors:  Noora Sjöstedt; Sibylle Neuhoff; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2020-11-06       Impact factor: 6.875

Review 7.  European guideline on indications, performance and clinical impact of 13 C-breath tests in adult and pediatric patients: An EAGEN, ESNM, and ESPGHAN consensus, supported by EPC.

Authors:  Jutta Keller; Heinz F Hammer; Paul R Afolabi; Marc Benninga; Osvaldo Borrelli; Enrique Dominguez-Munoz; Dan Dumitrascu; Oliver Goetze; Stephan L Haas; Bruno Hauser; Daniel Pohl; Silvia Salvatore; Marc Sonyi; Nikhil Thapar; Kristin Verbeke; Mark R Fox
Journal:  United European Gastroenterol J       Date:  2021-06-14       Impact factor: 4.623

Review 8.  Pre-procedural Preparation and Sedation for Gastrointestinal Endoscopy in Patients with Advanced Liver Disease.

Authors:  Brian M Fung; Deanna J Leon; Lauren N Beck; James H Tabibian
Journal:  Dig Dis Sci       Date:  2021-06-24       Impact factor: 3.487

9.  T2* Mapping from Multi-Echo Dixon Sequence on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging for the Hepatic Fat Quantification: Can It Be Used for Hepatic Function Assessment?

Authors:  Hyunsuk Yoo; Jeong Min Lee; Jeong Hee Yoon; Hyo-Jin Kang; Sang Min Lee; Hyun Kyung Yang; Joon Koo Han
Journal:  Korean J Radiol       Date:  2017-05-19       Impact factor: 3.500

Review 10.  Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.

Authors:  Mohamed Bouattour; Eric Raymond; Shukui Qin; Ann-Lii Cheng; Uz Stammberger; Giuseppe Locatelli; Sandrine Faivre
Journal:  Hepatology       Date:  2018-02-01       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.